Publications by authors named "Oliver Bechter"

34Publications

Improved resolution and sensitivity of [F]MFBG PET compared with [I]MIBG SPECT in a patient with a norepinephrine transporter-expressing tumour.

Eur J Nucl Med Mol Imaging 2020 May 8. Epub 2020 May 8.

Nuclear Medicine, University Hospitals Leuven, UZ Leuven, Campus Gasthuisberg, Herestraat 49, BE-3000, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04830-xDOI Listing
May 2020

Myositis as a neuromuscular complication of immune checkpoint inhibitors.

Acta Neurol Belg 2020 Apr 29;120(2):355-364. Epub 2020 Jan 29.

Department of Neurology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13760-020-01282-wDOI Listing
April 2020

Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.

Pharmacol Ther 2020 04 11;208:107479. Epub 2020 Jan 11.

Leuven Cancer Institute, Department of General Medical Oncology, University Hospitals Leuven, Belgium; Department of Oncology, KU, Leuven, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2020.107479DOI Listing
April 2020

Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.

Acta Derm Venereol 2019 07 17;99(12):1154-1159. Epub 2019 Jul 17.

Department of Dermatology, University Hospitals Leuven, Herestraat 49, BE-3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3270DOI Listing
July 2019

Gastric Tumoral Melanosis: a Rare Manifestation of Successfully Treated Malignant Melanoma.

Clin Gastroenterol Hepatol 2020 Jul 8;18(8):A37-A38. Epub 2019 Feb 8.

Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.02.006DOI Listing
July 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.

Melanoma Res 2017 10;27(5):507-510

aDepartment of General Medical Oncology bDepartment of Human Genetics, Center for Human Genetics cDepartment of Pathology dDepartment of Oncological Surgery eDepartment of Dermatology, University Hospitals KU Leuven, Leuven fDepartment of Hematology and Medical Oncology, ;CHR East Belgium, Verviers, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000376DOI Listing
October 2017

Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.

Melanoma Res 2017 04;27(2):164-167

aDepartment of General Medical Oncology, University Hospitals KU Leuven, Leuven bDepartment of Hematology and Medical Oncology, CHR East Belgium, Verviers, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000320DOI Listing
April 2017

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.

Cancer Chemother Pharmacol 2016 Jul 11;78(1):83-90. Epub 2016 May 11.

Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven - University of Leuven, 3000, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3056-0DOI Listing
July 2016

Inter-telomeric recombination is present in telomerase-positive human cells.

Cell Cycle 2013 Jul 6;12(13):2084-99. Epub 2013 Jun 6.

Department for Internal Medicine I, University Hospital Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.25136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737311PMC
July 2013

Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.

Anticancer Res 2011 Dec;31(12):4407-12

Innsbruck Medical University, Department of Internal Medicine I, Anichstrasse 35, 6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
December 2011

Detection of circular telomeric DNA without 2D gel electrophoresis.

DNA Cell Biol 2008 Sep;27(9):489-96

Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dna.2008.0741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242040PMC
September 2008

The frequency of homologous recombination in human ALT cells.

Cell Cycle 2004 May 10;3(5):547-9. Epub 2004 May 10.

UT Southwestern Medical Center, Dallas, Texas 75390-9039, USA.

View Article

Download full-text PDF

Source
May 2004

Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency.

EMBO Rep 2003 Dec 14;4(12):1138-43. Epub 2003 Nov 14.

Department of Cell Biology, Southwestern Medical Center, The University of Texas, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
http://embor.embopress.org/cgi/doi/10.1038/sj.embor.7400027
Publisher Site
http://dx.doi.org/10.1038/sj.embor.7400027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1326419PMC
December 2003

Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin.

Regul Pept 2002 Apr;105(1):35-46

Department of Internal Medicine, Division of General Internal Medicine, Faculty of Medicine, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0167-0115(01)00379-2DOI Listing
April 2002

CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia.

Exp Hematol 2002 Jan;30(1):26-33

Department of General Internal Medicine, Innsbruck University Hospital, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0301-472x(01)00760-3DOI Listing
January 2002